A version of this story appeared in Volume 101, Issue 36 Not too long ago, these small-molecule drugs looked as if they were going out of fashion. Advances in biotechnology enabled pharmaceutical ...
Biomea Fusion is a clinical-stage company focused on developing covalent small molecules for diabetes and genetically-defined cancers. The company highlighted positive phase 2 trial results for its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results